Search

Displaying results 6681 - 6690 of 8974 in total
  1. Drug

    Dapivirine

    go.drugbank.com/drugs/DB08639
    Investigational

    Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.

  2. Drug

    Heparan-N-sulfatase (human, recombinant)

    go.drugbank.com/drugs/DB18483
    Investigational

    Recombinant human heparan-N-sulfatase (rhHNS) is under investigation for the treatment mucopolysaccharidosis type IIIA.

  3. Drug

    Utomilumab

    go.drugbank.com/drugs/DB15113
    Investigational

    Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

  4. Drug

    Fluocortin

    go.drugbank.com/drugs/DB13223
    Experimental

    Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain [A174817].

  5. Drug

    Atopaxar

    go.drugbank.com/drugs/DB12046
    Investigational

    Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome.

  6. Drug

    AZD-7762

    go.drugbank.com/drugs/DB12242
    Investigational

    AZD7762 has been investigated for the treatment of Cancer, Solid Tumors, and Advanced Solid Malignancies.

  7. Drug

    Epirizole

    go.drugbank.com/drugs/DB08991
    Experimental

    Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.

  8. Drug

    BMS-986141

    go.drugbank.com/drugs/DB14942
    Investigational

    BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).

  9. Drug

    V116517

    go.drugbank.com/drugs/DB16060
    Investigational

    V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).

  10. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.